Theralase Technologies Inc. V.TLT

Exactly How Does TLD1433 Kill Cancer Cells?

[Eoganacht]

Dr. McFarland intends to spend the next 3 years finding out, financed by an NSF award of $440,000. 

"...insight regarding the potential photobiological mechanism(s) of TLD1433 and related PSs could lead to the development of Ru(II) photodrugs with even better properties than TLD1433."

Restricted Research - Award List, Note/Discussion Page

Restricted Research - Award List, Note/Discussion Page

 

Fiscal Year: 2021

 

1330  The University of Texas at Arlington  (85626)

 

Principal Investigator: Sherri McFarland

 

Total Amount of Contract, Award, or Gift (Annual before 2011): $ 440,000

 

Exceeds $250,000 (Is it flagged?): Yes

 

Start and End Dates: 8/1/21 - 7/31/24

 

Restricted Research: New/Blank/Unresolved/Undetermined

 

Academic Discipline: College of Science

 

Department, Center, School, or Institute: Department of Chemistry and Biochemistry

 

Title of Contract, Award, or Gift: The Excited State Behavior of Ru(II) Photodrugs

 

Name of Granting or Contracting Agency/Entity: National Science Foundation (NSF)

CFDA Link: NSF

47.049

 

Program Title: Division of Chemistry: Disciplinary Research Programs (CHE-DRP)

CFDA Linked: Mathematical and Physical Sciences

 

Note:

 

The project will examine the excited state behavior of our TLD1433 and related Ru(II) photodrugs. We propose a new mechanism that may account for the very high photocytotoxicity that certain oligothiophene-containing Ru(II) photodrugs show toward cancer cells, both in normoxia and in hypoxia. The project also aims to develop the photophysical model(s) for these photosensitizers (PSs) in complex biological environments. More broadly, this work will generate new knowledge about the relationships between molecular structure, redox chemistry and photophysics, and potentially novel photocytotoxic mechanisms. This insight regarding the potential photobiological mechanism(s) of TLD1433 and related PSs could lead to the development of Ru(II) photodrugs with even better properties than TLD1433. Obj 1: We will synthesize and characterize oligothiophene-appended Ru(II) PSs, [Ru(LL)2(IP-nT)]2+, that differ in the number of thiophene rings (nT), the types of substituents on the thiophene rings, and the coligands (LL). The modifications are designed to vary redox potentials and triplet state characteristics and to alter the covalent and noncovalent associations typical of oligothiophenes. Obj 2: Electrochemical techniques will be used to test the hypothesis that the Ru(II) PSs can participate in biological photoredox catalysis, where biomolecules can be oxidized (or reduced) by a catalytic PS* with or without oxygen. The purpose is to show that photoredox catalysis is possible using simple biological substrates. (SAM Category: 1.1.1)

[CancerSlayer]

Thanks again for sharing Eoganacht... It's nice to know this technology/compound has the support of the NSF.  Did a little digging & such awards aren't handed out like candy...approximately 75% of competitive proposals get rejected annually.  All of your tireless unfunded DD deserves a very generous payday.  GLTA...

[steamfitter]

In my opinion and believe this will extend the time period for TLT running out the clock. In my opinion I also believe that it keeps the doctor and lab financed for the next four years. No need then to push this into comercial production for bladder cancer.  Everyone happy but the stock holders in my opinion.  We need answers now as to the results of phase 2. If it works great if it do

[Eoganacht]

Whether Dr. McFarland gets a grant or not has zero effect on the trial. She does not work for Theralase - Theralase just has the rights to use the photodynamic compounds she has already created and Theralase will have those rights for many years to come. Whatever Dr. McFarland decides to do, Theralase's current and future trials with TLD1433, Rutherrin and thouands of her other

[steamfitter]

There is a time period. It is not forever.I believe it is less than 4 years left.  Ask the question of how long Theralase holds the rights. Ask the investment people at Theralase. This is just my opinion. Good luck to all investors. 

[Eoganacht]

"US patent number 9,345,769 (filed on April 15, 2013 and issued on May 24, 2016) provides patent protection for tens of thousands of metal based PDCs; including, Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation by the Company for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”).   The US patent provides patent protection for Theralase’s second

[NorCalTommy]

Kudos to Sherri for the NSF grant! Question:    If better, more effective photodrugs than TLD 1433 are discovered, would TLT need to start back at square 1 with phase 1 trials OR would the new more effective drugs be inserted in place of TLD 1433 in the 'Process'.....   i would think there would need to be some testing of the 'new improved photodrug' but to

[ScienceFirst]

NorCalTommy ... Having been invested in TLT for so long and having vomited on TLT management in all your posts, it's surprizing that you don't even know the answer to your basic question! A new molecule has to go through all the testing steps, as this is ... a new molecule.  Science measures.  Doesn't make assumptions. You'd be the first to blame regulatory bodies for